Identification

Generic Name
Magnesium Aluminum Silicate
DrugBank Accession Number
DB11230
Background

Magnesium aluminum silicate is a naturally occurring mineral obtained from silicate ores of the montmorillonite group 1. It is refined to a powder for use in cosmetic and pharmaceutical applications as an absorbent, anticaking agent, opacifying agent, viscosity-increasing agent, suspending agent, tablet and capsule disintegrant, and tablet binder. It also has antacid properties and is used as a component of some over the counter antacid medications.

Type
Small Molecule
Groups
Approved
Synonyms
  • Aluminii magnesii silicas
  • Aluminium magnesium silicate
  • Aluminium magnesium silicate hydrate
  • Aluminium magnesium silicate polyhydrate
  • Aluminum magnesium silicate
  • Magnesium aluminium silicate
  • Magnesium aluminium silicate hydrate
  • Magnesium aluminum silicate hydrate
External IDs
  • M-907015
  • MJ-2000

Pharmacology

Indication

Magnesium aluminum silicate is used as an over the counter antacid for the self-treatment of heartburn, sour stomach, or acid indigestion Label.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Magnesium aluminum silicate neutralizes excess acid in the stomach to reduce or eliminate symptoms of heartburn, sour stomach, or acid indigestion Label

Mechanism of action

Magnesium aluminum silicate reacts with acid in the stomach to increase the pH.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The LD50 in mice is considered to be >50000 mg/kg with oral suspensions of magnesium aluminum silicate 1. The dermal LD50 is considered to be >3.5 g/kg observed in rabbits. Magnesium aluminum silicate produced mild skin irritation. In a 90 day study in rats, animal fed a diet with 20% magnesium aluminum silicate had slightly stunted growth. With 5% and 10% the rats had increased silicone content in the spleen. At 2% one male rat died and at 10% one male and female rat died. These rats had fibrous exudates in the thorax and hemorrhage in the lungs with evidence of infection. No evidence of teratogenicity or mutagenicity was found in the appropriate studies.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium Aluminum Silicate.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium Aluminum Silicate.
Botulinum toxin type AThe risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum toxin type A.
Botulinum toxin type BThe risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum toxin type B.
CapreomycinThe risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium Aluminum Silicate.
ChloroquineThe risk or severity of neuromuscular blockade can be increased when Chloroquine is combined with Magnesium Aluminum Silicate.
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium Aluminum Silicate.
ClindamycinThe risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Magnesium Aluminum Silicate.
ColistimethateThe risk or severity of neuromuscular blockade can be increased when Colistimethate is combined with Magnesium Aluminum Silicate.
ColistinThe risk or severity of neuromuscular blockade can be increased when Colistin is combined with Magnesium Aluminum Silicate.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Veegum

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
6M3P64V0NC
CAS number
1327-43-1

References

General References
  1. Elmore AR: Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. Int J Toxicol. 2003;22 Suppl 1:37-102. [Article]
RxNav
17614
Wikipedia
Pyrope
FDA label
Download (306 KB)
MSDS
Download (47 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsolubleMSDS
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 03, 2015 16:51 / Updated at January 07, 2021 03:13